"Designing Growth Strategies is in our DNA"
Leishmaniasis is a parasitic disease caused by a protozoa parasite from over 20 Leishmania species. Leishmaniasis is found in parts of the subtropics, tropics, and southern Europe. Leishmania parasites can be spread by the bite of phlebotomine sand flies. There are three main forms of leishmaniasis; such as visceral leishmaniasis, cutaneous leishmaniasis, and mucocutaneous leishmaniasis. According to WHO most cases of visceral leishmaniasis occur in Brazil, East Africa and in South-East Asia. An estimated 50, 000 to 90,000 new cases of visceral leishmaniasis occur worldwide each year out of which only an estimated 25–45% are reported to WHO.
Management of visceral leishmaniasis can be done using liposomal amphotericin B. Antiparasitic pentavalent antimonial agents, Liposomal amphotericin B, Pentamidine, oral miltefosine, and other drugs are used for the treatment of leishmaniasis.
Academic research institutes and research laboratories have focused on studying and developing new treatment options for the Leishmaniasis. For instance; WR 279,396 topical cream, which is being studied by U.S. Army Medical Research and Materiel Command, is currently in phase-3 clinical trials for the treatment of cutaneous leishmaniasis.
To know how our report can help streamline your business, Speak to Analyst
At present around 50% of the pipeline candidates for Leishmaniasis are in the phase-2 stage. Majority of the studies have been sponsored by universities and research institutes.
The report on ‘Leishmaniasis – Pipeline Review, 2019’ provides a comprehensive overview of the drugs that are in the R&D pipeline by indication or molecule for Leishmaniasis. The report provides a thorough analysis of the distribution of the pipeline products by clinical trial stage, indication, company, therapy area and details such as clinical trial stage, sponsor, description on every product in the pipeline. Products in the preclinical and clinical stage along with dormant & discontinued pipeline candidates are included in the report. The report also covers additional insights such as epidemiology overview and current market scenario for Leishmaniasis.
The report on ‘Leishmaniasis – Pipeline Review, 2019’, which is built by following a robust research methodology involving primary interviews and desk research, provides a complete overview of the R&D activity and pipeline products to assist companies in developing growth strategies and identifying emerging players.